IPF

IPF
Name	Idiopathic pulmonary fibrosis
Field	Pulmonology
Symptoms	Progressive dyspnea, dry cough
Complications	Respiratory failure, pulmonary hypertension
Onset	Middle to late adulthood
Duration	Chronic, progressive

IPF

Idiopathic pulmonary fibrosis is a chronic, progressive interstitial lung disease characterized by scarring of the pulmonary interstitium leading to restrictive physiology and impaired gas exchange. It typically presents in middle-aged to older adults and carries substantial morbidity and mortality, prompting involvement from respiratory centers, specialist clinics, and multidisciplinary teams across academic hospitals and research institutes. Clinical care pathways often connect referral networks including tertiary centers, transplant programs, and guideline-producing bodies.

Signs and symptoms

Patients commonly present with exertional dyspnea, a persistent dry cough, and progressive exercise intolerance. Physical examination may reveal bilateral inspiratory crackles, digital clubbing, and signs of right ventricular strain in advanced cases, prompting referrals to centers such as Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, and national pulmonary programs. Symptom trajectories often lead clinicians to order imaging at institutions like Massachusetts General Hospital or consult guidelines from organizations such as the American Thoracic Society and the European Respiratory Society. Comorbid presentations can include secondary pulmonary hypertension, frequent exacerbations that result in hospital admission at regional hospitals, and symptom overlap with other interstitial lung diseases treated at specialized centers including Royal Brompton Hospital and university departments at University of California, San Francisco.

Causes and risk factors

By definition the etiology is unknown, but epidemiological associations implicate environmental exposures, host factors, and aging. Risk factors include cigarette smoking, occupational dust exposures encountered in mining and shipbuilding communities linked to historical cohorts like workers from Pittsburgh, familial clustering evaluated at research centers such as National Institutes of Health, and gastroesophageal reflux disease assessed in specialty clinics. Genetic predisposition has been described through mutations and telomerase pathway variants studied at institutions such as Broad Institute and Harvard Medical School, while comorbid autoimmune conditions seen at centers like Mayo Clinic can complicate differential diagnosis. Male sex, advanced age, and prior radiation or certain drug exposures tracked in pharmacoepidemiology registries are also associated with increased risk.

Pathophysiology

Pathological hallmarks include heterogeneous fibrosis, fibroblastic foci, and architectural lung distortion with honeycombing typically involving subpleural and basal regions. Fibrogenic pathways engage alveolar epithelial injury, aberrant wound repair, and profibrotic mediators such as transforming growth factor-beta studied in laboratories at Imperial College London and Karolinska Institutet. Cellular contributors include activated myofibroblasts and altered epithelial-mesenchymal interactions characterized in basic science programs at Cold Spring Harbor Laboratory and Max Planck Institute for Molecular Cell Biology. Repeat microinjury hypotheses draw on observations in cohorts from centers like Johns Hopkins Hospital and translational models developed at University of Cambridge and Stanford University. Progressive fibrosis leads to impaired diffusion capacity, increased work of breathing, and ultimately cor pulmonale described in cardiopulmonary collaborations at Royal Infirmary of Edinburgh.

Diagnosis

Diagnosis relies on integration of clinical, radiological, and, when needed, histopathological data via multidisciplinary discussion involving pulmonologists, radiologists, and pathologists from institutions such as Mayo Clinic, Guy's and St Thomas' NHS Foundation Trust, and university hospital networks. High-resolution computed tomography performed at imaging centers including Mount Sinai Hospital often demonstrates usual interstitial pneumonia patterns with reticulation and honeycombing. Pulmonary function testing at centers like Karolinska University Hospital reveals restrictive deficits and reduced diffusing capacity. When radiology is indeterminate, surgical lung biopsy or cryobiopsy may be performed with pathology evaluated against criteria developed by the American Thoracic Society and European Respiratory Society; multidisciplinary teams convene similarly to those at University College London.

Treatment and management

Management combines antifibrotic therapy, supportive care, and consideration of lung transplantation. Antifibrotic agents licensed following trials at academic centers include pirfenidone and nintedanib, with prescription and monitoring protocols used at specialty clinics such as Vanderbilt University Medical Center and Toronto General Hospital. Supportive measures encompass supplemental oxygen therapy, pulmonary rehabilitation programs established at institutions like Cleveland Clinic, vaccination strategies coordinated with public health agencies, and palliative care referrals as practiced at comprehensive cancer and chronic disease centers including St. Jude Children's Research Hospital for symptom frameworks. Advanced disease may lead to evaluation for lung transplantation at centers of excellence including Papworth Hospital and UCLA Medical Center.

Prognosis and outcomes

Prognosis is variable but often grave, with median survival historically around 3–5 years from diagnosis in many cohorts studied by registries at European Respiratory Society and national databases such as those maintained by National Heart, Lung, and Blood Institute. Predictors of worse outcome include accelerated decline in forced vital capacity, acute exacerbations requiring hospitalization at tertiary centers, and development of pulmonary hypertension managed by cardiopulmonary programs at Mount Sinai Hospital. Antifibrotic therapy has altered disease trajectories in randomized trials conducted at collaborating universities and pharmaceutical partners, improving rates of lung function decline and influencing transplant referral timing.

Epidemiology and prevention methods

Incidence and prevalence vary geographically and by registry reporting from countries with surveillance systems at ministries of health and academic networks like University of Toronto and Karolinska Institutet. Reported incidence increases with age and is higher in populations with historical industrial exposures tracked in occupational health studies from Pittsburgh and Glasgow. Preventive strategies focus on smoking cessation programs run by public health agencies, exposure mitigation in occupational settings regulated by bodies such as Occupational Safety and Health Administration and workplace health services, vaccination campaigns, and early detection initiatives led by specialist clinics and primary care networks affiliated with major hospitals. Research consortia including the Pulmonary Fibrosis Foundation coordinate registries and clinical trials to refine prevention and care pathways.

Category:Pulmonology